Seres Therapeutics (MCRB) Leases (2019 - 2025)
Historic Leases for Seres Therapeutics (MCRB) over the last 7 years, with Q3 2025 value amounting to $74.7 million.
- Seres Therapeutics' Leases fell 993.97% to $74.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.7 million, marking a year-over-year decrease of 993.97%. This contributed to the annual value of $80.9 million for FY2024, which is 1052.24% down from last year.
- Latest data reveals that Seres Therapeutics reported Leases of $74.7 million as of Q3 2025, which was down 993.97% from $76.8 million recorded in Q2 2025.
- Seres Therapeutics' Leases' 5-year high stood at $111.0 million during Q4 2022, with a 5-year trough of $8.4 million in Q1 2021.
- Its 5-year average for Leases is $66.2 million, with a median of $78.9 million in 2025.
- Its Leases has fluctuated over the past 5 years, first soared by 50953.43% in 2022, then tumbled by 2564.63% in 2025.
- Seres Therapeutics' Leases (Quarter) stood at $18.2 million in 2021, then soared by 509.53% to $111.0 million in 2022, then dropped by 18.53% to $90.4 million in 2023, then decreased by 10.52% to $80.9 million in 2024, then fell by 7.71% to $74.7 million in 2025.
- Its last three reported values are $74.7 million in Q3 2025, $76.8 million for Q2 2025, and $78.9 million during Q1 2025.